

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
3 July 2008 (03.07.2008)

PCT

(10) International Publication Number
WO 2008/077897 A1

(51) International Patent Classification:

C05D 9/02 (2006.01) **C07D 213/38** (2006.01)
C07C 229/36 (2006.01) **C07C 229/76** (2006.01)
C07D 207/32 (2006.01)

Departamento de Química Agrícola, Facultad de Ciencias,
CVII, E-08049 Madrid (ES).

(74) Agent: **BARLOCCI, Anna**; ZBM Patents, S. L., Balmes,
114 4^o, E-08008 Barcelona (ES).

(21) International Application Number:

PCT/EP2007/064370

(22) International Filing Date:

20 December 2007 (20.12.2007)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

06127041.9 22 December 2006 (22.12.2006) EP

(71) Applicant (for all designated States except US):
TRADECORP, S. A. [ES/ES]; C/. Alcalá, 498, 2^a
planta, E-28027 Madrid (ES).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **SIERRA, Miguel A.** [ES/ES]; Universidad Complutense, Departamento de Química Orgánica, Facultad de Química, E-28040 Madrid (ES). **GÓMEZ-GALLEGO, Mar** [ES/ES]; Universidad Complutense, Departamento de Química Orgánica, Facultad de Química, E-28040 Madrid (ES). **ESCUDERO, Rosa** [ES/ES]; Universidad Complutense, Departamento de Química Orgánica, Facultad de Química, E-28040 Madrid (ES). **LUCENA, Juan J.** [ES/ES]; Universidad Autónoma, Departamento de Química Agrícola, Facultad de Ciencias, CVII, E-28049 Madrid (ES). **GARCÍA-MARCO, Sonia** [ES/ES]; Universidad Autónoma,

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

Published:

— with international search report
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(54) Title: NEW PRODUCTS FOR THE TREATMENT OF THE IRON CHLOROSIS

(57) Abstract: The present invention consists on the synthesis of new products for the treatment of the iron chlorosis. These products may have improved properties regarding the currently known treatments. The new products are non-symmetrical ethylene diamino hidroxyphenyl acetic acid derivatives possessing only five coordination sites able to chelate metals.



WO 2008/077897 A1

New products for the treatment of the iron chlorosis

Field of the invention

This invention relates to new non-symmetrical ethylene diamino
5 hidroxyphenyl acetic acid derivatives. These products are useful for the
treatment of iron chlorosis.

BACKGROUND ART

10 Iron chlorosis is a nutritional plant disorder which results in a decrease in the
amount of chlorophyll and in the yellowing or whitening of normally green
plant tissue. It is a widespread problem in agriculture that affects the
development of many crops provoking a decrease yield.

15 Attempts have long been made to correct this iron deficiency by feeding the
plants with iron in assimilable form, originally in the form of ferric salts. Ferric
salts act to a certain extent by foliar penetration, but are substantially
ineffectual when used for soil treatment. It is through the roots that the
penetration of iron is at its most effective in controlling chlorosis. In this
20 connection, simple iron salts have been replaced by iron chelates which are
hydrosoluble complexes consisting of an iron atom attached to several points
of a single organic molecule known as chelates or co-ordinates. Some of
these products known as hexadentates, such as complexes of iron with
ethylene diamine tetracetic acid (EDTA) or with diethylene triamine pentacetic
25 acid (DTPA) or with N,N'-ethylene-bis-(hydroxyphenyl)glycines (EDDHA),
have been successfully used against chlorosis.

N,N'-ethylene-bis(2-hydroxyphenyl)glycine (*o,o*-EDDHA) is often described as
one of the most favorable compounds for complexing metals, and being most
30 suitable for the use as a plant nutrient or fertilizer because the complexation
affinity to iron is particularly strong. The ferric chelate of *o,o*-EDDHA shows a
coordination number of 6 and is widely used for agrochemical purposes as a
plant nutrient or plant fertilizer, and for the treatment of chlorosis in crop
plants.

35 The N,N'-ethylene-(2-hydroxyphenyl)-glycinyI-(4-hydroxyphenyl)glycine (*o,p*-
EDDHA) is also known in the art. Contrary to *o,o*-EDDHA, in the *o,p*-EDDHA

isomer one of the hydroxy groups is in the *para*- position of the benzene ring. For this reason, the ferric chelate of *o,p*-EDDHA shows a coordination number of 5 and its complexation affinity to iron is weaker than that of *o,o*-EDDHA. This compound has often being regarded as an undesired by-product being incurred by the manufacturing process of *o,o*-EDDHA.

Gómez-Gallego *et al.* (c.f. *Chem.Eur.J.* **2005**, *11*, 5997 -6005) propose a model for explaining the reduction of the Fe(III)-*o,o*-EDDHA chelate by a ferric chelate reductase. According to it, the reduction of said chelate does not take place on the complex in the octahedral closed form, wherein the 6 chelating points of *o,o*-EDDHA are coordinated to the Fe(III), but on a hexacoordinate open species formed at the acid pH of the rhizosphere. As showed in Scheme 5 of said report, one of the hydroxy groups in the *ortho*-position would not be coordinated with the Fe(III), thus generating a vacant coordination site that would be filled with a water molecule. The complex Fe(III)-*o,p*-EDDHA, wherein one of the hydroxy groups is in the *para*- position, would already be in the required open form and could be reduced directly by the enzyme.

WO2005/095305 discloses isomeric mixtures comprising both (*o,o*-EDDHA) and (*o,p*-EDDHA) , wherein the molar ratio of (*o,p*-EDDHA) to (*o,o*-EDDHA) is higher than 0.8 : 1, as nutrients for agricultural crop plants and agents for treatment of chlorosis in such plants.

SUMMARY OF THE INVENTION

The properties of the commercially available chelating agents currently used for the treatment of iron deficiency related plant diseases (e.g. iron chlorosis), such as those based in EDDHA and known derivatives thereof, are still not completely satisfactory. For instance, it has been observed that current chlorosis treatments based on *o,o*-EDDHA show a delayed effect in plants. WO2005/095305 proposes to solve this problem by employing isomeric mixtures of *o,o*-EDDHA and *o,p*-EDDHA, as said above. However, *o,p*-EDDHA/Fe³⁺ shows lower stability than *o,o*-EDDHA/Fe³⁺. (Yunta et al. *Journal of Agricultural and Food Chemistry*, **2003**, *51*, 5391-5399) so it is quite reactive in soils.

Properties that are desirable in a compound useful for the treatment of iron chlorosis are described in Lucena, J.J. *Iron Fertilizers in Correcting Iron Deficiencies in Plants*. Chapter 5, *In Iron Nutrition in Plants and Rhizospheric Microorganism* 2006, pp 103-127, Springer-Verlag Academic Publishers.

5

The problem to be solved by the present invention is to provide alternative products that may be useful for the treatment of iron deficiency related plant diseases. These products may have improved properties regarding the currently known treatments.


10

The solution is based on the fact that the present inventors have identified that by eliminating one of the carboxylic groups of EDDHA and maintaining or modulating the hydroxyphenyl groups, the chelating affinity for polyvalent metals, particularly for iron, is retained, while some other properties may be improved, particularly those that make them useful for the treatment of iron chlorosis. See working examples 1-7 herein for a further description.

15

Accordingly, a first aspect of the invention relates to a compound of formula (I):

20



25

(I)

wherein

30


X^1 is a C_6 or a C_{10} aromatic system having a hydroxy group in the alpha position, being optionally substituted by up to four substituents independently selected from the group consisting of: phospho, sulfo, halo, carboxy, acetoxy, C_1 - C_4 alkoxy or linear or branched C_1 - C_4 alkyl.

35

X^2 is a C_6 or a C_{10} aromatic system having a hydroxy group in the alpha position, or a five or six membered heterocycle having in the alpha position a heteroatom selected from the group consisting of N, O and S, optionally comprising other N, O or S atoms in their structure, and having from 0-3 double bonds, said aromatic, or heterocyclic system being optionally

substituted by up to four substituents independently selected from the group consisting of: phospho, sulfo, halo, carboxy, acetoxy, C₁-C₄ alkoxy, linear or branched C₁-C₄ alkyl.


- 5 Y is (CH₂)_n or is a xylylene group of formula:



n is an integer selected from 2, 3 and 4,

- 10 R¹, R² are independently selected from the group consisting of H, linear or branched C₁-C₄ alkyl, C₆ or C₁₀ aryl.

In a second aspect the invention relates to a process for preparing a compound of formula (I) as defined in the first aspect of the invention and in its corresponding embodiments, which process comprises the step of
15 reducing a compound of formula (II):



wherein X¹, X² and Y are as defined above, in an appropriate solvent system, in the presence of a reducing agent.


- 25 In a third aspect the invention relates to the use of a compound of formula (I), as defined in the first aspect of the invention and its corresponding embodiments, as a complex forming agent for polyvalent metals.

- 30 In a fourth aspect the invention relates to a chelate of a compound of the formula (I), as defined in the first aspect of the invention and its corresponding embodiments, with one or more polyvalent metals.

- 35 In a fifth aspect the invention relates to an agrochemical composition comprising a compound of formula (I), as defined in the first aspect of the invention and its corresponding embodiments, or a polyvalent metal chelate thereof.

In a sixth aspect the invention relates to the use of a compound, as defined in the first aspect of the invention and its corresponding embodiments, or a polyvalent metal chelate thereof, for the preparation of a composition for treating an iron deficiency related plant disease.

In a seventh aspect the invention relates to an intermediate of formula (II):



(II)

wherein X^1 , X^2 and Y are as defined above, in solid form.

In a eighth aspect the invention relates to the use of the intermediate of formula (II) as defined in the seventh aspect of the invention and its corresponding embodiments, for the preparation of a compound of formula (I), as defined in the first aspect of the invention and its corresponding embodiments.

Without wishing to be bound by theory, as reported in *Chem. Eur. J.* **2005**, *11*, 5997, the effectiveness of Fe(III)-*o,o*-EDDHA to relief iron chlorosis requires the generation of a vacant coordination site. This fact explains the high efficiency of *o,p*-EDDHA a compound in which one of the phenolic groups is unable to coordinate the metal. Advantageously the new compounds described in the invention have only five groups able to coordinate with the metal. This point should be essential for their activity.

Furthermore, most of the derivatives of EDDHA known in the art and employed for the treatment of iron deficiency related plant diseases are symmetrical compounds, except for the *o,p*-EDDHA, which is an isomer of EDDHA. On the contrary, all the compounds of formula (I) are non-symmetrical compounds, since they lack one of the two carboxylic groups of EDDHA. Therefore, the known methods for the preparation of EDDHA derivatives were not directly applicable to the compounds of the invention. This has forced the inventors to develop a new method of synthesis for preparing the said compounds of formula (I).

Throughout the description and claims the word "comprise" and variations of the word, such as "comprising", is not intended to exclude other technical features, additives, components, or steps. The content of the application from
5 which priority is claimed, as well as the contents of the abstracts of the priority application and the present application, are incorporated herein as reference.

Additional objects, advantages and features of the invention will become
10 apparent to those skilled in the art upon examination of the description or may be learned by practice of the invention. The following examples are provided by way of illustration, and it is not intended to be limiting of the present invention.

BRIEF DESCRIPTION OF THE DRAWINGS

15 Figure 1 shows the SPAD index of the fourth level, represented versus the days of treatment, for plants grown on soil treated with each of the tested compounds and the control.

20 Figure 2 shows the dry weight of shoots (expressed in grams) in the soil experiment, with the tested compounds and the control, at three sampling times.

25 Figure 3 shows the iron concentration in leaves of the plants treated with the tested compounds and the control, at three sampling times.

Definitions

30 By linear or branched C₁-C₄ alkyl, is taken to mean herein a linear or branched alkyl group which contains up to 4 atoms of carbon. Thus it includes, for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl and tert-butyl.

35 By C₁-C₄ alkoxy it is meant herein the alkyl groups mentioned above bound through oxygen, examples of which include methoxy, ethoxy, isopropoxy, tert-butoxy, and the like.

The term halo, in this invention, refers to F, Cl, Br, I, preferably Cl.

A C₆ or a C₁₀ aromatic system or a C₆ or a C₁₀ aryl group include phenyl and naphthyl.

5

DETAILED DESCRIPTION OF PARTICULAR EMBODIMENTS

As defined above, X² in the compounds of formula (I) is a C₆ or a C₁₀ aromatic system having a hydroxy group in the alpha position, or a five or six
10 membered heterocycle having in the alpha position a heteroatom selected from the group consisting of N, O and S, optionally comprising other N, O or S atoms in their structure, and having from 0-3 double bonds, said aromatic, or heterocyclic system being optionally substituted by up to four substituents independently selected from the group consisting of: phospho, sulfo, halo,
15 carboxy, acetoxy, C₁-C₄ alkoxy, linear or branched C₁-C₄ alkyl. Heterocycle as meant herein includes both non-aromatic heterocycles (e.g. 2-azetidiny, 2-pyrrolidyl, 2-piperidiny), and heteroaromatic rings. Preferably said heterocycle is heteroaromatic.

20 Preferred compounds of formula (I) are those wherein X² is selected from the group consisting of 2-hydroxyphenyl, 2-hydroxy-naphthyl, 2-furyl, 2-thienyl, 2-pyrrolyl, 2-pyridyl, 4-pyridimidiny, 2-pyrazinyl optionally substituted by 2 or 1 substituents independently selected from the group consisting of: phospho, sulfo, halogen, C₁-C₄ alkoxy, carboxy, acetoxy, linear or branched C₁-C₄ alkyl.
25 Preferred optional substituents include methyl, phenyl, phospho, sulfo, carboxy, acetyl.

More preferred compounds of formula (I) are those wherein X¹ is 2-hydroxyphenyl or 2-hydroxynaphthyl, optionally substituted by 2 or 1
30 substituents independently selected from the group consisting of methyl or methoxy. Yet more preferred are those wherein X¹ is 2-hydroxyphenyl.

In the compounds of formula (I), preferably Y is (CH₂)_n, and more preferably n is 2. When Y is a xylylene group as defined above, preferably both R¹ and R²
35 are H.

In a preferred embodiment, compounds of formula (I) are those wherein Y is


(CH₂)_n, and more preferably n is 2, X¹ is 2-hydroxyphenyl, X² is selected from the group consisting of 2-hydroxyphenyl, 2-hydroxynaphthyl, 2-furyl, 2-thienyl, 2-pyrrolyl, 2-pyridyl, 4-pyridimidinyl, 2-pyrazinyl, optionally substituted by 2 or 1 substituents independently selected from the group consisting of: C₁-C₄ alkyl, C₁-C₄ alkoxy, carboxy, sulfo, acetoxy .

The most particularly preferred compounds are selected from the group consisting of:

2-(2-((2-hydroxybenzyl)amino)ethylamino)-2-(2-hydroxyphenyl)acetic acid,
 2-(2-((2-hydroxy-1-naphthyl)methylamino)ethylamino)-2-(2-hydroxyphenyl)acetic acid,
 2-(2-((pyridin-2-yl)methylamino)ethylamino)-2-(2-hydroxyphenyl)acetic acid,
 2-(2-((1H-pyrrol-2-yl)methylamino)ethylamino)-2-(2-hydroxyphenyl)acetic acid.

Preferred methods include, but are not limited to, those described below. The reactions are carried out in the solvents appropriate for the reagents and materials used and suited for the transformations carried out. An expert in organic synthesis will understand that the functional groups present in the molecule must be consistent with the proposed transformations. This may in some cases require modifying the order of the synthesis steps or selecting one particular method rather than another, in order to obtain the desired compound of the invention. Moreover, in some of the procedures described below it may be desirable or necessary to protect the reagent functional groups present in the compounds or intermediates of this invention with conventional protecting groups. Various protecting groups and procedures for introducing them and removing them are described in Greene and Wuts (*Protective Groups in Organic Synthesis*, Wiley and Sons, 1999). All the references cited herein are incorporated integrally by reference.

The compounds of formula (I) as defined above, can be prepared by a process which comprises the step of reducing a compound of formula (II):




wherein X^1 , X^2 and Y are as defined above, in an appropriate solvent system, in the presence of a reducing agent.

The reaction may be carried out in different solvent systems. Suitable solvent systems include C_1 - C_4 alcohols such as methanol and ethanol, acetic acid, water and mixtures thereof. Preferably the reaction is carried out in methanol.


Suitable reducing agents are hydrides and hydrogen with a metal catalyst. Preferably, the reducing agent is selected from the group consisting of borohydrides, such as sodium cyanoborohydride, sodium triacetoxyborohydride, sodium borohydride. Better results are obtained when the reducing agent used is sodium borohydride or Pd hydrogenation.

The reaction is preferably carried out at temperature ranging from 15°C to 40°C. Better results are obtained when carried out from 18°C to 25°C.

In a preferred embodiment, the process for preparing a compound of formula (I) according to the second aspect of the invention, further previously comprises the step of preparing said compound of formula (II) by reacting a compound of formula (III) with a compound of formula (IV):



(III)



(IV)

wherein X^1 , X^2 and Y are as defined above, in an appropriate solvent system.

The reaction between a compound of formula (III) with a compound of formula (IV) may be carried out in different solvent systems. Suitable solvent systems include C_1 - C_4 alcohols such as methanol and ethanol; water; nitriles such as acetonitrile; ketones such as 2-butanone; and mixtures thereof. Preferably the reaction is carried out in methanol, ethanol, water or mixtures thereof.

In a preferred embodiment, the reaction between a compound of formula (III) with a compound of formula (IV), and the subsequent reduction of the

compound of formula (II) obtained to prepare a compound of formula (I) is carried out as a one pot reaction.

5 The best conditions to carry out the process vary according to the parameters considered by the person skilled in the art, such as the starting materials, temperature and similar. Such reaction conditions may be easily determined by the person skilled in the art by routine tests, and with the teaching of the examples included in this document.

10 Compounds of formula (III) are described in the literature and/or can be prepared by methods analogous to those known in the state of the art (e.g. in US 5,679,704, DE3329028 A1 and WO-2006045852 A1) from products commercially available.

15 A compound of formula (I) as defined above may be used as a complex forming agent for polyvalent metals. Preferably, said polyvalent metal is at least one polyvalent metal selected from the group consisting of iron, nickel, zinc, manganese, ytterbium, gadolinium, cobalt and copper. More preferably, said metal is iron.

20 A compound of the formula (I) as defined above may form chelates with one or more polyvalent metals. Preferably, said polyvalent metal is at least one polyvalent metal selected from the group consisting of iron, nickel, zinc, manganese, ytterbium, gadolinium, cobalt, copper, palladium, platinum and, 25 gold. More preferably, said metal is iron. Such iron chelates may further contain e.g. an alkali-or alkaline earth metal, like sodium, potassium, calcium or magnesium, particularly sodium.

30 Chelates according to the invention may be used as active component in agriculturally acceptable compositions, as sole active component or in combination with other agriculturally active components, such as plant nutrients or plant fertilizers. Thus, agrochemical compositions according to the invention comprise a compound of formula (I) as defined above, or a metal chelate thereof. Said compositions may further comprise agriculturally 35 acceptable carriers. The composition is preferably applied in the form of a solution or suspension by injecting into the soil.

The other agriculturally acceptable active ingredients may be additional fertilizers, micronutrient donors or other preparations that influence plant growth and development or plant protection products like selective herbicides or insecticides, fungicides, bactericides, nematocides, molluscicides, or mixtures of several of such preparations, if desired.

Agriculturally acceptable active ingredients also include other chelating agents. Said chelating agents include ethylene diamine tetracetic acid (EDTA), diethylene triamine pentacetic acid (DTPA), o,o-EDDHA and o,p-EDDHA. In one embodiment, the agrochemical compositions of the invention also comprise o,o-EDDHA.

Agriculturally acceptable carriers may be natural or regenerated mineral substances, solvents, dispersants, wetting agents, tackifiers, thickeners or binders. Such carriers and additives are described, for example, in WO 95/30651.

The compounds of formula (I) according to the invention are useful for treating an iron deficiency related plant disease. Preferably, said disease is iron chlorosis.

Preferred intermediates of formula (II) are those wherein X^1 is 2-hydroxyphenyl.

EXAMPLES

Example 1: 2-(2-((2-hydroxybenzyl)amino)ethylamino)-2-(2-hydroxyphenyl)acetic acid

Step 1. Intermediate of formula (II) (X^1 = 2-hydroxyphenyl, Y = $(CH_2)_2$, X^2 = 2-hydroxybenzyl)

To a solution of the 2-(2-aminoethylamino)-2-(2-hydroxyphenyl)acetic acid hydrochloride in water at pH 7.3, was added an equimolar amount of salicylaldehyde in ethanol. After stirring for 1 h at room temperature, the title Schiff base was filtered and obtained as a solid in 80% yield.

^1H -NMR (300 MHz, DMSO- d_6 , 2.5, ppm): δ = 8.54 (s, 1H, CH=N), 7.48 (d, 1H, J = 7.5 Hz, Ar), 7.34 (t, 1H, J = 7.62 Hz, Ar), 7.30 (d, 1H, J = 7.32 Hz, Ar), 7.18

(m, 1H, Ar), 6.92-6.70 (m, 4H, Ar), 4.62 (s, 1H, CH), 3.83 (m, 4H, CH₂), 3.15 (m, 1H, CH₂), 3.02 (m, 1H, CH₂).

Step 2. 2-(2-((2-hydroxybenzyl)amino)ethylamino)-2-(2-hydroxyphenyl)acetic acid

- 5 The hydrogenation of the of the Schiff base obtained in Step 1 in MeOH (10 % Pd/C) at room temperature yielded the title product as brown solid (80%).

¹H-NMR (500 MHz, D₂O, 4.8(HDO), ppm): δ = 7.20-7 (m, 4H, Ar), 6.79-6.66 (m, 4H, Ar), 4.36 (s, CH), 3.87 (s, 2H, CH₂), 2.84-2.69 (m, 4H, CH₂).

10 **Example 2: 2-(2-((2-hydroxy-1-naphtyl)methylamino)ethylamino)-2-(2-hydroxyphenyl)acetic acid.**

Step 1. Intermediate of formula (II) (X¹= 2-hydroxyphenyl, Y=(CH₂)₂, X²=2-hydroxy-1-naphtyl)

15

Following Example 1, but starting from equimolar amounts of 2-(2-aminoethylamino)-2-(2-hydroxyphenyl)acetic acid hydrochloride and 1-formyl-β-naphtol the the Schiff base of the title was obtained as yellow solid in 70% yield.

- 20 ¹H-NMR (300 MHz,DMSO, 2.5, ppm): δ = 9.11 (s, 1H, CH-N), 8.055 (d, 1H, J = 8.35 Hz, Ar), 7.72 (d, 1H, J = 9.44 Hz, Ar), 7.63 (d, 1H, J = 7.10 Hz, Ar), 7.42 (d, 2H, J = 7.07 Hz, Ar), 7.25 (d, 1H, J = 9.44 Hz, Ar), 7.17 (d, 2H, J = 7.11 Hz, Ar), 6.75-6.67 (m, 2H, Ar), 4.43 (s, 1H), 3.86-3.78 (m, 2H, CH₂), 3.2-3.02 (m, 1H CH₂), 2.92-2.8 (m, 1H, CH₂).

25

Step 2. 2-(2-((2-hydroxy-1-naphtyl)methylamino)ethylamino)-2-(2-hydroxyphenyl)acetic acid

- A mixture of equimolar amounts of the Schiff base obtained in Step 1, NaBH₃CN and a catalytic amount of Zn₂Cl in MeOH was stirred at room temperature for 3 h. The solvent was removed by evaporation and the title product was obtained as brown solid (85% yield).

- 30 ¹H-NMR (500 MHz, D₂O, 4.8 (HDO), ppm): δ = 7.7-7.55 (m, 3H, Ar), 7.45-7.37 (m, 1H, Ar), 7.3-7.15 (m, 2H, Ar), 7.06 (d, 1H, J = 5.67 Hz, Ar), 6.95 (d, 1H, J = 9.17 Hz, Ar), 6.8-7.2 (m, 2H, Ar), 5.02 (s, 1H), 4.23(s, 2H), 3.22-3.073 (m, 4H).

35

Example 3: 2-(2-((pyridin-2-yl)methylamino)ethylamino)-2-(2-hydroxyphenyl)acetic acid

5

Step 1. Intermediate of formula (II) (X^1 = 2-hydroxyphenyl, Y = $(CH_2)_2$, X^2 = pyridin-2-yl)

The procedure of Example 1 is followed, but starting from equimolar amounts of 2-(2-aminoethylamino)-2-(2-hydroxyphenyl)acetic acid hydrochloride and 2-pyridinecarboxaldehyde at pH 7. After 20 h at room temperature the solvent was removed and the title Schiff base was obtained as yellow solid in 90% yield.

^1H -NMR (300 MHz, DMSO, 2.5, ppm): δ = 8.63 (bs, 1H, J = 4.77 Hz, CH=N), 8.5-8.1 (m, 1H, Ar), 8.0-7.84 (m, 2H, Ar), 7.46 (t, 1H, Ar J = 6.58 Hz), 7.21-7.1 (m, 1H, Ar), 7.05-6.95 (m, 1H, Ar), 6.88-6.73 (m, 2H, Ar), 4.59 (s, 1H, CH), 3.9 (m, 2H, CH_2), 3.1-3.0 (m, 2H, CH_2).

Step 2. 2-(2-((pyridin-2-yl)methylamino)ethylamino)-2-(2-hydroxyphenyl)acetic acid

A mixture of equimolar amounts of the Schiff base obtained in Step 1 and $NaBH_4$ in MeOH was stirred at room temperature for 20 h. The solvent was removed by evaporation and the title product was obtained as white solid (95% yield).

^1H -NMR (300 MHz, D_2O , 4.8 (HDO) ppm): δ = 8.4-8.36 (m, 1H, Ar), 7.82 (td, 1H, J_1 = 7.65 Hz, J_2 = 1.38 Hz, Ar), 7.77-7.72 (m, 2H, Ar), 7.36-7.25 (m, 2H, Ar), 7.2-7.0 (m, 1H, Ar), 6.74-6.65 (m, 1H, Ar), 4.38 (s, CH), 3.76 (s, 2H, CH_2), 2.78-2.6 (m, 4H, CH_2).

Example 4: 2-(2-((1H-pyrrol-2-yl)methylamino)ethylamino)-2-(2-hydroxyphenyl)acetic acid

30

Step 1. Intermediate of formula (II) (X^1 = 2-hydroxyphenyl, Y = $(CH_2)_2$, X^2 = 1H-pyrrol-2-yl)

Following the procedure of Example 1, but starting from equimolar amounts of 2-(2-aminoethylamino)-2-(2-hydroxyphenyl)acetic acid hydrochloride and pyrrole-2-carboxaldehyde, the title Schiff base was obtained after stirring at room temperature for 20 h as orange solid in 90% yield.

¹H-NMR (300 MHz, DMSO, 2.5, ppm): δ = 8.09 (s, 1H, CH=N), 7.35-7.20 (m, 1H, Ar), 7.0-6.95 (m, 1H, Ar), 6.87 (s, 1H, Ar), 6.75-6.65 (m, 1H, Ar), 6.5-6.4 (m, 1H, Ar), 6.3-6.2 (m, 1H, Ar), 6.115-6.05 (m, 1H, Ar), 4.11 (s, 1H, CH), 3.65-3.5 (m, 2H, CH₂), 2.9-2.6 (m, 2H, CH₂).

5

Step 2. *2-(2-((1H-pyrrol-2-yl)methylamino)ethylamino)-2-(2-hydroxyphenyl)acetic acid*

A mixture of equimolar amounts of the Schiff base obtained in Step 1 and NaBH₄ in MeOH was stirred at room temperature for 20 h. The solvent was removed by evaporation and the title product was obtained as orange solid (94% yield).

10

¹H-NMR (500 MHz, D₂O, 4.8(HDO), ppm): δ = 7.2-7.1. (m, 2H, Ar), 6.80-6.69 (m, 3H, Ar), 6.15-6.25 (m, 2H, Ar), 4.44 (s, 1H), 3.70 (s, 2H, CH₂), 2.85-2.6 (m, 4H, CH₂).

15

Example 5: 2-(2-((imidazol-4(5)-yl)methylamino)ethylamino)-2-(2-hydroxyphenyl)acetic acid

Step 1. Intermediate of formula (II) (X¹= 2-hydroxyphenyl, Y=(CH₂)₂, X²=imidazol-4(5)-yl)

20

To a solution of the 2-(2-aminoethylamino)-2-(2-hydroxyphenyl)acetic acid hydrochloride in water at pH 7.2, was added an equimolar amount of 4(5)-formylimidazole in methanol. After stirring for 24 h at room temperature, the title Schiff base was filtered and obtained as a solid in quantitative yield.

25

¹H-NMR (300 MHz, CD₃OD, 3.31 ppm): δ = 8.21 (broad s, 1H, CH=N), 7.76 (s, 1H, CH=N), 7.49 (s, 1H, CH=N), 7.23 (dt, 1H, J₁ = 7.56 Hz, J₂ = 1.35 Hz, Ar), 7.10 (td, 1H, J₁ = 1.38 Hz, J₂ = 7.56 Hz, Ar), 6.77 (m, 2H, Ar), 5.74 (1H, NH), 4.44 (s, 1H, CH), 3.72-3.70 (m, 2H, CH₂), 3.08-3.0 (m, 1H, CH₂), 2.95-2.34 (m, 1H, CH₂).

30

Step 2. *2-(2-((imidazol-4(5)-yl)methylamino)ethylamino)-2-(2-hydroxyphenyl)acetic acid*

The hydrogenation of the Schiff base obtained in Step 1 in MeOH (10 % Pd/C) at room temperature yielded the title product as a solid (35%).

35

¹H-NMR (500 MHz, D₂O, 4.8 (HDO) ppm): δ = 7.55 (s, 1H, C=N), 7.06-7.0.3 (m, 2H, Ar), 6.88 (s, 1H, C=N), 6.68-6.64 (m, 2H, Ar), 4.33 (s, 1H, CH), 3.59 (s, 2H, CH₂), 2.76-2.56 (m, 4H, CH₂).

Example 6: 2-(2-((1H-imidazol-2-yl)methylamino)ethylamino)-2-(2-hydroxyphenyl)acetic acid

5

Step 1. Intermediate of formula (II) (X^1 = 2-hydroxyphenyl, Y = $(CH_2)_2$, X^2 = 1H-imidazol-2-yl)

To a solution of the 2-(2-aminoethylamino)-2-(2-hydroxyphenyl)acetic acid hydrochloride in water at pH 7.2, was added an equimolar amount of 2-formylimidazole in methanol. After stirring for 24 h at room temperature, the title Schiff base was filtered and obtained as a solid in quantitative yield.

^1H -RMN (500 MHz, CD_3OD , 3.31 ppm) δ = 8.24 (broad s, 1H, CH=N), 7.18 (s, 2H, CH=N), 7.10-6.97 (m, 2H, Ar), 6.79-6.73 (m, 2H, Ar), 5.72 (broad s, 1H, NH), 4.36 (s, 1H, CH), 3.79-3.75 (m, 2H, CH_2), 3.03-2.94 (m, 1H, CH_2), 2.89-2.84 (m, 1H, CH_2).

Step 2. 2-(2-((1H-imidazol-2-yl)methylamino)ethylamino)-2-(2-hydroxyphenyl)acetic acid

The hydrogenation of the of the Schiff base obtained in Step 1 in MeOH (10 % Pd/C) at room temperature yielded the title product as a solid (34%).

^1H -RMN (500 MHz, D_2O , 4.8 (HDO) ppm) δ = 7.55 (s, 1H, C=N), 7.06-7.03 (m, 2H, Ar), 6.88 (s, 1H, C=N), 6.68-6.64 (m, 2H, Ar), 4.33 (s, 1H, CH), 3.59 (s, 2H, CH_2), 2.76-2.56 (m, 4H, CH_2).

Example 7: 2-(2-((piperidin-2-yl)methylamino)ethylamino)-2-(2-hydroxyphenyl)acetic acid

Step 1. Intermediate of formula (II) (X^1 = 2-hydroxyphenyl, Y = $(CH_2)_2$, X^2 = piperidin-2-yl)

To a solution of the 2-(2-aminoethylamino)-2-(2-hydroxyphenyl)acetic acid hydrochloride in water at pH 7.2, was added an equimolar amount of 2-formyl-N-terbutoxycarbonyl-piperidine in methanol. After stirring for 24 h at room temperature, the title Schiff base was filtered and obtained as a solid in quantitative yield.

^1H -NMR (300 MHz, $DMSO-d_6$, 2.5, ppm): δ = 7.57 (s, 1H, C=N), 7.28-7.26 (m, 2H, Ar), 7.0- 6.96 (m, 2H, Ar), 4.5 (s, 1H, CH), 4.14-4.05 (m, 1H, CH), 3.3-2.80 (m, 6H, CH_2), 1.49-1.36 (m, 6H, CH_2), 1.36 (s, 9H, CH_3).

Step 2. 2-(2-((piperidin-2-yl)methylamino)ethylamino)-2-(2-hydroxyphenyl)acetic acid

5 The hydrogenation of the of the Schiff base obtained in Step 1 in MeOH (10 % Pd/C) at room temperature, followed by removal of the tertbutoxycarbonyl (BOC) group with 1 mL of 10% H₂SO₄ in 10 mL dioxane, 24 h at room temperature, yielded the title product as a solid (60%).

10 ¹H-RMN (500 MHz, D₂O, 4.8 (HDO) ppm): δ = 7.21-7.16 (m, 2H, Ar), 6.72-6.67 (m, 2H, Ar), 4.35 (s, 1H, CH), 3.56-3.51 (m, 1H, CH), 3.1-2.52 (m, 8H, CH₂), 1.49-1.45 (m, 2H, CH₂), 1.13-1.03 (m, 4H, CH₂).

Example 8: 2-(2-((pyrrolidin-2-yl)methylamino)ethylamino)-2-(2-hydroxyphenyl)acetic acid

15

Step 1. Intermediate of formula (II) (X¹ = 2-hydroxyphenyl, Y = (CH₂)₂, X² = pyrrolidin-2-yl)

To a solution of the 2-(2-aminoethylamino)-2-(2-hydroxyphenyl)acetic acid hydrochloride in water at pH 7.2, was added an equimolar amount of 2-formyl-N-terbutoxycarbonyl-pyrrolidine in methanol. After stirring for 24 h at room temperature, the title Schiff base was filtered and obtained as a solid in quantitative yield.

20 ¹H-RMN (500 MHz, DMSO-*d*₆, 2.5, ppm): δ = 7.57 (broad s, 1H, C=N), 7.27 (d, 1H, *J* = 7.35 Hz, Ar), 7.01- 6.91 (m, 1H, Ar), 6.66- 6.59 (m, 2H, Ar), 4.6 (m, 1H, CH), 3.92 (s, 1H, CH), 2.71-2.6 (m, 1H, CH₂), 2.59-2.45 (m, 1H, CH₂), 25 1.99-1.75 (m, 4H, CH₂), 1.38-1.37 (m, 2H, CH₂), 1.37 (s, 9H, CH₃).

Step 2. 2-(2-((pyrrolidin-2-yl)methylamino)ethylamino)-2-(2-hydroxyphenyl)acetic acid

30 The hydrogenation of the of the Schiff base obtained in Step 1 in MeOH (10 % Pd/C) at room temperature, followed by removal of the BOC group with 1 mL of 10% H₂SO₄ in 10 mL dioxane, 24 h at room temperature, yielded the title product as a solid (50%).

35 ¹H-RMN (500 MHz, D₂O, 4.8 (HDO) ppm): δ = 7.31-7.26 (m, 2H, Ar), 6.91-6.87 (m, 2H, Ar), 5.1 (s, 1H, CH), 3.9-3.83 (m, 1H, CH), 3.44-3.20 (m, 8 H, CH₂), 1.96-1.65 (m, 4 H, CH₂).

Example 9: 2-(2-((2-hydroxybenzyl)amino)ethylamino)-2-(2-hydroxy-4-methylphenyl)acetic acid

5

Step 1. Intermediate of formula (II) (X^1 = 2-hydroxy-4-methylphenyl, $Y=(CH_2)_2$, X^2 = 2-hydroxybenzyl)

To a solution of the 2-(2-aminoethylamino)-2-(2-hydroxy-4-methylphenyl)acetic acid hydrochloride in water at pH 7.2, was added an
10 equimolar amount of salicylaldehyde in ethanol. After stirring for 1 h at room temperature, the title Schiff base was filtered and obtained as yellow solid in 65% yield.

$^1\text{H-NMR}$ (300 MHz, DMSO- d_6 , 2.5, ppm): δ = 8.54 (s, 1H, CH=N), 7.45 (d, 1H, J = 7.78 Hz, Ar), 7.33 (td, 1H, J_1 = 1.63 Hz, J_2 = 8.2 Hz, Ar), 7.08 (d, 1H, J = 7.7 Hz, Ar), 6.9 (t, 2H J = 7.27 Hz Ar), 6.61-6.58 (m, 2H, Ar), 4.56 (s, 1H, CH), 3.85-3.81 (m, 2H, CH_2), 3.17-3.09 (m, 1H, CH_2), 3.09-2.95 (m, 1H, CH_2), 2.18 (s, 3H, CH_3).

Step 2. 2-(2-((2-hydroxybenzyl)amino)ethylamino)-2-(2-hydroxy-4-methylphenyl)acetic acid

The hydrogenation of the of the Schiff base obtained in Step 1 in MeOH (10 % Pd/C) at room temperature yielded the title product as brown solid (75%).

$^1\text{H-NMR}$ (500 MHz, D_2O , 4.8 (HDO), ppm): δ = 7.22-7.1 (m, 3H, Ar), 6.72-6.64 (m, 4H, Ar), 4.37 (s, 1H, CH), 3.92 (s, 2H, CH_2), 2.59-2.81 (m, 4H, CH_2), 2.23
25 (s, 3H, CH_3).

Example 10: 2-(2-((2-hydroxybenzyl)amino)ethylamino)-2-(2-hydroxy-5-methylphenyl)acetic acid

Step 1. Intermediate of formula (II) (X^1 = 2-hydroxy-5-methylphenyl, $Y=(CH_2)_2$, X^2 = 2-hydroxybenzyl)

To a solution of the 2-(2-aminoethylamino)-2-(2-hydroxy-5-methylphenyl)acetic acid hydrochloride in water at pH 7.2, was added an
35 equimolar amount of salicylaldehyde in ethanol. After stirring for 1 h at room temperature, the title Schiff base was filtered and obtained as yellow solid in 52% yield.

¹H-NMR (300 MHz, DMSO-*d*₆, 2.5, ppm): δ = 8.55 (s, 1H, C=N), 7.45 (d, 1H, *J* = 7.6 Hz, Ar), 7.32 (t, 1H, *J* = 8.81 Hz, Ar), 7.02 (s, 1H, Ar), 6.90 (t, 3H, *J* = 7.56 Hz, Ar), 6.68 (d, 1H, *J* = 8.13, Ar), 4.52 (s, 1H, CH), 3.85-3.80 (m, 2H, CH₂), 3.2.-3.12 (m, 1H, CH₂), 3.01- 2.94 (s, 1H, CH₂) , 2.17 (s, 3H, CH₃).

5

Step 2. 2-(2-((2-hydroxybenzyl)amino)ethylamino)-2-(2-hydroxy-5-methylphenyl)acetic acid

The hydrogenation of the of the Schiff base obtained in Step 1 in MeOH (10 % Pd/C) at room temperature yielded the title product as brown solid (70%).

10 ¹H-NMR (500 MHz, D₂O, 4.8 (HDO), ppm): δ = 7.18 (t, 1H, *J* = 6.14 Hz, Ar), 7.2-7.15 (m, 2H, Ar), 6.92-6.89 (s, 1H, Ar), 6.89-6.68 (m, 3H, Ar), 5.15 (s, 1H, CH), 4.16 (s, 2H, CH₂), 3.36-3.19 (m, 4H, CH₂), 2.19 (s, 3H, CH₃).

15 **Example 11: Preparation of ferric chelates**

The general procedure used for preparing the ferric chelates of the invention is the following:

20 To a solution of the ligand of formula (I) in NaOH (1:3 ligand:NaOH molar ratio), is added a solution of the equimolar amount of FeCl₃·6H₂O in water. During the addition, the pH of the solution should be maintained between 6.0-8.0 by addition of NaOH or HCl, and finally adjusted to 7. The final solution is filtered through 0.45 μm cellulose membranes before use.

25 **Example 12: Determination of Titrimetric purity of the chelating agent**

Photometric titration

30 Chelating agent solution was prepared by dissolving an amount of chelating agent in the necessary amount of NaOH solution. Then pH is adjusted to 6 by the addition of MES biological buffer [2-(N-morpholino) ethanesulfonic acid] and maintaining at this pH with NaOH solution during the titration. Ionic strength is fixed at 0.1M with NaCl and upper atmosphere was N₂ free of CO₂. The test solution was placed in a thermostated jacketed reaction vessel
35 (i.e.100 ml or 150 ml capacity) with an airtight cap fitted with gas inlet and outlet tubes, the combined pH glass electrode, the photometric detector and two piston burettes, tip extending below the surface of the solution, and a

magnetic stirrer. The photometric titration consisted of the addition of a Fe(III) standard solution, previously standardized by Atomic Absorption Spectroscopy, to the chelating agent until the absorbance at 480 nm presents no changes. End-point titration could be calculated for two linear segments' intersection and also using smoothed second derivative method.

Potentiometric titration

The chelating agent purities could also be determined by potentiometric titrations with a Cu^{2+} ion selective electrode in the same conditions as before. The chelating agent solution is titrated with Cu(II) solution using selective Cu(II) electrode and reference electrode, Cu^{2+} free cation is measured with the selective electrode. The end-point of the potentiometric titrations could be determined by Gran equation method or using the first derivative method. Previously, the Cu(II) solution used as titrant solution is standardize with EDTA- Na_2 solution and the selective electrode slope is determined by titration of NaCl solution fixed at pH=6 with Cu(II) as titrant solution.

Example 13: Determination of agrochemical activity

Efficacy of Fe chelates to provide Fe to soybean plants in hydroponics.

Soybean seeds (Glycine max L. cv. Stine 0480) were germinated at 30 °C and 60% RH on paper moistened with 1 M CaSO_4 in dark for 2 days. Afterwards, seedlings were placed in 10 L containers (50 seedlings per container) filled with a 1/5 diluted EDTA buffered nutrient solution (macronutrients (mM)- 1.0 $\text{Ca}(\text{NO}_3)_2$, 0.9 KNO_3 , 0.3 MgSO_4 , 0.1 KH_2PO_4 ; cationic micronutrients (μM)- 5.0 EDTA/ Fe^{3+} , 2.5 MnSO_4 , 1.0 CuSO_4 , 10 ZnSO_4 , 1.0 CoSO_4 , 1.0 NiCl_2 , 115.5 Na_2EDTA ; anionic micronutrients (μM)- 35 NaCl , 10 H_3BO_3 , 0.05 Na_2MoO_4 ; 0.1 mM HEPES) for 6 days. On the 7th day, in order to induce Fe chlorosis, seedlings were transferred to 12 L polypropylene buckets containing aerated full strength EDTA buffered nutrient solution but without Fe^{3+} -chelate. Plants were grown under these conditions until clear symptoms of Fe deficiency were observed (7 days) and then plants were placed in 2 L pots (6 plants per pot) covered with black plastic to avoid light exposure. The effect of different Fe chelates and doses

were compared as Fe sources. Chelates used in the treatments were *o,o*-EDDHA/Fe³⁺, *o,p*-EDDHA/Fe³⁺, EDTA/Fe³⁺ and Example 1/Fe³⁺. The last one is the Fe chelate of the compound of the example 1: 2-(2-((2-hydroxybenzyl)amino)ethylamino)-2-(2-hydroxyphenyl)acetic acid (DCHA).

5 Nutrient solution contained macronutrients and anionic micronutrients as for the seedling period and the following cationic micronutrients composition: (μM) 1.0 MnSO₄, 0.5 CuSO₄, 0.5 ZnSO₄, 0.1 NiCl₂ and 0.1 CoSO₄. Also, 1g·L⁻¹ of CaCO₃ was added to the nutrient solution to buffer pH at 7.5 and to simulate conditions of a calcareous soil. Plants were grown for 21 days in this

10 nutrient solution in a growth chamber provided with fluorescent and sodium vapour lamps with a 16 h/30 °C and 50% humidity day and 8 h/25 °C and 70% humidity night regime. Water was added every 2 days and the nutrient solution was renewed every 7 days. Treatments were replicated four times in a completely randomised design. Plants were harvested after 7, 14 and 21

15 days.

During the experiment, SPAD readings with a chlorophyll-meter (Minolta SPAD-502) were taken for all leaf stages (average of two or three readings per stage) every second day. Only values measured for the youngest fully

20 open leaves (the 2nd stage at the 2nd day, the third at the 10th day and the fourth at the 20th day) are here presented (Table 1)

Table 1. Effects of Fe chelates treatments on the SPAD index measured.

Treatments	SPAD		
	Time after treatments (days)		
	2 (2nd stage)	10 (3rd stage)	20 (4th stage)
T0 Control (without Fe)	5.0 d	3.4 d	-
T1 5μM Example 1/Fe ³⁺	8.4 abc	32.8 a	34.8 a
T2 10 μM Example 1/Fe ³⁺	8.8 ab	35.7 a	35.0 a
T3 5 μM <i>o,o</i> -EDDHA/Fe ³⁺	6.2 cd	26.7 b	30.2 a
T4 10 μM <i>o,o</i> -EDDHA/Fe ³⁺	9.1 ab	31.6 ab	32.4 a
T5 5 μM <i>o,p</i> -EDDHA/Fe ³⁺	8.1 abc	30.9 ab	32.2 a
T6 10 μM <i>o,p</i> -EDDHA/Fe ³⁺	10.4 a	33.1 a	32.9 a

T7 5 μ M EDTA/Fe ³⁺	6.8 bcd	6.9 d	11.4 c
T8 10 μ M EDTA/Fe ³⁺	8.1 abc	16.6 c	19.9 b

Different letters in the columns denote significant differences ($\alpha=0.05$) among treatments according to the Duncan Test

The chlorophyll and the recovery of plants after the treatments application were estimated by the SPAD index. Table 1 shows the time course of this parameter. Two days after the treatment application, plants treated with 10 μ M *o,p*-EDDHA/Fe³⁺ showed the highest SPAD index values but it only showed significant differences with 5 μ M *o,o*-EDDHA/Fe³⁺, 5 μ M EDTA/Fe³⁺ and –Fe treatments. Ten days after, plants treated with 5 μ M and 10 μ M Example 1/Fe³⁺ and 10 μ M *o,p*-EDDHA/Fe³⁺ had significantly regreened in relation to 5 μ M *o,o*-EDDHA/Fe³⁺, 5 μ M and 10 μ M EDTA/Fe³⁺ and –Fe treatments. At the end of the experiment (20 days after the treatments application), regardless of the doses, plants treated with Example 1, *o,o*-EDDHA and *o,p*-EDDHA Fe chelates (T1, T2, T3, T4, T5 and T6) had completely regreened showing significant SPAD index values concerning 5 μ M and 10 μ M doses of EDTA/Fe³⁺ and –Fe treatments.

Considering the low doses applied and the trend observed, we can conclude that the product obtained in Example 1 presents a fast action to correct iron chlorosis, similar to *o,p*-EDDHA, but higher than *o,o*-EDDHA.

Root and shoot were separated and washed using Tween 80 (Merck) and HCl solution and fresh and dry (after oven dry procedure) weights were determined. Samples were ground and after dry digestion in a muffle furnace (480 °C), ashes are dissolved in HCl. Fe, Mn, Cu and Zn were analysed by atomic absorption spectrometry.

In Table 2 the Fe content in the plants in each sampling time for the treatments with the lower Fe application is presented. It can be observed that

the novel compound Example 1/ Fe^{3+} is able to provide significantly higher amounts of iron and faster in this experimental conditions than the other treatments, even more than *o,p*-EDDHA in the third sampling time. However, when a large doses of Fe is used (10 μM , table 3) differences are only significant respect the treatment with EDTA/ Fe^{3+} . It can be concluded that Example 1/ Fe^{3+} can be used in lower concentration than other chelates to correct the iron chlorosis.

Table 2 Fe content (μg Fe per plant) in plants treated with the low doses of chelates

Fe content (μg Fe per plant)			
	1st sampling 7 days after treatment	2nd sampling 14 days after treatment	3rd sampling 21 days after treatment
Control (without Fe)	20.3 c	10.0 c	11.2 c
5 μM Example 1/ Fe^{3+}	57.4 a	152 a	268 a
5 μM <i>o,o</i> -EDDHA/ Fe^{3+}	26.0 bc	83.6 b	202 b
5 μM <i>o,p</i> -EDDHA/ Fe^{3+}	43.0 ab	128 a	223 b
5 μM EDTA/ Fe^{3+}	14.2 c	19.6 c	22.6 c

Different letters in the columns denote significant differences ($\alpha = 0.05$) among treatments according to the Duncan Test.

Table 3 Fe content (μg Fe per plant) in plants treated with the high doses of chelates

Fe content (μg Fe per plant)			
	1st sampling 7 days after treatment	2nd sampling 14 days after treatment	3rd sampling 21 days after treatment
Control (without Fe)	20.3 b	10.0 b	11.2 b
10 μM Example 1/ Fe^{3+}	69.3 a	136 a	235 a
10 μM o,o-EDDHA/ Fe^{3+}	61.4 a	129 a	254 a
10 μM o,p-EDDHA/ Fe^{3+}	77.8 a	129 a	259 a
10 μM EDTA/ Fe^{3+}	27.7 b	32.6 b	47.6 b

Different letters in the columns denote significant differences ($\alpha = 0,05$) among treatments according to the Duncan Test.

Efficacy of Fe chelates to provide Fe to soybean plants in soil conditions

5 Soybean seeds (Glycine max L. cv. Stine 0480) were germinated at 30 °C and 60% RH on paper moistened with 1 M CaSO_4 in dark for 2 days. Afterwards, seedlings were placed in 10 L containers (50 seedlings per container) filled with a 1/5 diluted EDTA buffered nutrient solution

10 (macronutrients (mM)- 1.0 $\text{Ca}(\text{NO}_3)_2$, 0.9 KNO_3 , 0.3 MgSO_4 , 0.1 KH_2PO_4 ; cationic micronutrients (μM)- 5.0 EDTA/ Fe^{3+} , 2.5 MnSO_4 , 1.0 CuSO_4 , 10 ZnSO_4 , 1.0 CoSO_4 , 1.0 NiCl_2 , 115.5 Na_2EDTA ; anionic micronutrients (μM)- 35 NaCl , 10 H_3BO_3 , 0.05 Na_2MoO_4 ; 0.1 mM HEPES) for 4 days. Then, in order to induce Fe chlorosis, nutrient solution without iron was used for two

15 more days and then plants were transplanted in 1 L pots (3 plants per pot) containing 700 g of a calcareous soil (380 $\text{mg}\cdot\text{Kg}^{-1}$ calcium carbonate, 89 g $\cdot\text{Kg}^{-1}$ CaCO_3 active, pH 7.70) and 300 g of lime sand covered with black plastic to avoid light exposure. The effect of different Fe chelates were compared as Fe sources: o,o-EDDHA/ Fe^{3+} , o,p-EDDHA/ Fe^{3+} , EDTA/ Fe^{3+} and

20 Example 1/ Fe^{3+} . The last one is the Fe chelate of the compound of the example 1:

1: 2-(2-((2-hydroxybenzyl)amino)ethylamino)-2-(2-

hydroxyphenyl)acetic acid. Plants were grown for 21 days in this soil conditions in a growth chamber provided with fluorescent and sodium vapour lamps with a 16 h/30 °C and 50% humidity day and 8 h/25 °C and 70% humidity night regime. Treatments were replicated five times in a completely randomised design. Single plants were harvested after 2, 7 and 21 days.

During the experiment, SPAD readings with a chlorophyll-meter (Minolta SPAD-502) were taken for all leaf stages (average of two or three readings per stage) every second day. Values measured for the 2nd stage at the 2nd day, the third at the 12th day and the fourth and fifth at the 22th day) are here presented (Table 4).

Table 4. Effects of Fe chelates treatments on the SPAD index measured in the soil experiment

Treatments	SPAD			
	Time after treatments (days)			
	2	12	22	22
	(2nd stage)	(3rd stage)	(4th stage)	(5th stage)
Control (-Fe)	19.1	12.6	9.0	-
o,o-EDDHA/Fe ³⁺	22.4	42.1	34.1	28.8
o,p-EDDHA/Fe ³⁺	25.8	41.2	33.0	21.0
Example 1/Fe ³⁺	23.9	41.0	34.1	26.6

Different letters in the columns denote significant differences ($\alpha=0.05$) among treatments according to the Duncan Test.

All chelate treatments present higher SPAD indexes than control, as shown in Figure 1. This and the visual symptoms indicate that the recovery from chlorosis using these chelates was complete. Two days after the treatment application, plants treated with o,p-EDDHA/Fe³⁺ and Example 1/Fe³⁺ presented the better recovery, due to the fast action of these compounds, and

after that it is the treatment with the o,o-EDDHA/Fe³⁺ the one which gives the highest values but similar to Example 1/Fe³⁺.

5 In each sampling time shoots were separated and washed using Tween 80 (Merck) and HCl solution and fresh and dry (after oven dry procedure) weights were determined. Samples were ground and after dry digestion in a muffle furnace (480 °C), ashes were dissolved in HCl. Fe, Mn, Cu and Zn were analysed by atomic absorption spectrometry.


10 In Figure 2 the dry weight obtained for the shoots is presented. Again the Example 1/Fe³⁺ revealed as an efficient Fe chlorosis corrector. Also in Figure 3 the iron concentration in leaves is shown for the three sampling times. The three iron chelates considerably increase the Fe concentration with respect to the control.

15 From this experiment, with only one treatment application, we can conclude that the product obtained in Example 1 is efficient to solve iron chlorosis in highly calcareous conditions. Its efficacy is related with its fast action mechanism.

20

CLAIMS

1. A compound of formula (I):




(I)

wherein

X^1 is a C_6 or a C_{10} aromatic system having a hydroxy group in the alpha position, being optionally substituted by up to four substituents independently selected from the group consisting of: phospho, sulfo, halo, carboxy, acetoxy, C_1 - C_4 alkoxy, linear or branched C_1 - C_4 alkyl.

X^2 is a C_6 or a C_{10} aromatic system having a hydroxy group in the alpha position, or a five or six membered heterocycle having in the alpha position a heteroatom selected from the group consisting of N, O and S, optionally comprising other N, O or S atoms in their structure, and having from 0-3 double bonds, said aromatic, or heterocyclic system being optionally substituted by up to four substituents independently selected from the group consisting of: phospho, sulfo, halo, carboxy, acetoxy, C_1 - C_4 alkoxy, linear or branched C_1 - C_4 alkyl.

Y is $(\text{CH}_2)_n$ or is a xylylene group of formula:



n is an integer selected from 2, 3 and 4,

R^1 , R^2 are independently selected from the group consisting of H, linear or branched C_1 - C_4 alkyl, C_6 or C_{10} aryl.

2. The compound according to claim 1, wherein X^2 is selected from the group consisting of 2-hydroxyphenyl, 2-hydroxy-naphthyl, 2-furyl, 2-thienyl, 2-pyrrolyl, 2-pyridyl, 4-pyridimidinyl, 2-pyrazinyl optionally substituted by 2 or 1 substituents independently selected from the group consisting of: phospho,

sulfo, halogen, C₁-C₄ alkoxy carboxy, acetoxy, linear or branched C₁-C₄ alkyl.


3. The compound according to claim 2, wherein X¹ is 2-hydroxyphenyl or 2-hydroxynaphthyl, optionally substituted by 1 or 2 substituents independently selected from the group consisting of methyl or methoxy.

4. The compound according to claim 3, wherein X¹ is 2-hydroxyphenyl.

5. The compound according to any one of claims 1 to 4, wherein Y is (CH₂)_n



6. The compound according to claim 5, wherein n is 2.

7. A process for preparing a compound of formula (I) as defined in claims 1 to 6, which process comprises the step of reducing a compound of formula (II):



wherein X¹, X² and Y are as defined above, in an appropriate solvent system, in the presence of a reducing agent.

8. The process according to claim 7, further previously comprising the step of preparing said compound of formula (II) by reacting a compound of formula (III) with a compound of formula (IV):



wherein X¹, X² and Y are as defined above, in an appropriate solvent system.

9. Use of a compound of formula (I) as defined in claims 1 to 6 as a complex forming agent for polyvalent metals.

10. A chelate of a compound of the formula (I) as defined in any of claims 1 to 6 with one or more polyvalent metals.

11. A chelate according to claim 10, wherein said polyvalent metal is at least one polyvalent metal from the group consisting of iron, nickel, zinc, manganese, ytterbium, gadolinium, cobalt, copper, palladium, platinum and, gold.

12. The chelate according to claim 11, wherein said polyvalent metal is iron.


13. An agrochemical composition comprising a compound of formula (I) as defined in any of claims 1 to 6 or a polyvalent metal chelate thereof.

14. The agrochemical composition according to claim 13, further comprising a chelating agent selected from the group consisting of ethylene diamine tetracetic acid (EDTA), diethylene triamine pentacetic acid (DTPA), N,N'-ethylene-bis(2-hydroxyphenyl)glycine (*o,o*-EDDHA) and N,N'-ethylene-(2-hydroxyphenyl)-glycyl-(4-hydroxyphenyl)glycine (*o,p*-EDDHA).

15. Use of a compound as defined in claims 1 to 6 or a polyvalent metal chelate thereof for the preparation of a composition for treating an iron deficiency related plant disease.

16. The use according to claim 15, wherein said disease is iron chlorosis.

17. An intermediate of formula (II):



(II)

wherein X¹, X² and Y are as defined above, in solid form.

18. The intermediate of formula (II) according to claim 17, wherein X¹ is 2-hydroxyphenyl.

19. The intermediate of formula (II) according to claim 18, wherein Y is $(\text{CH}_2)_2$.
20. Use of the intermediate of formula (II) as defined in any of claims 17 to 19, for the preparation of a compound of formula (I), as defined in any of claims 1 to 6.
- 5

Fig. 1




Fig. 2





Fig. 3



INTERNATIONAL SEARCH REPORT

International application No
PCT/EP2007/064370

A. CLASSIFICATION OF SUBJECT MATTER

INV. C05D9/02 C07C229/36 C07D207/32 C07D213/38 C07C229/76

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

C05D C07C C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	PECORARO ET AL.: "Stepwise Metal-Assisted Oxidative Decarboxylation of Vanadium(V) Ethylenebis((o-hydroxyphenyl)glycine). Isolation of a possible intermediate" J. AM. CHEM. SOC., vol. 106, no. 11, 1984, pages 3360-3362, XP002437470 compound 3	17-19
X	XINHUA ET AL.: "Stepwise, Metal-assisted Decarboxylation promoted by Manganese: Reactivity Relationship between Manganese and Vanadium" INORG. CHEM., vol. 28, 1989, pages 3403-3410, XP002437471 figure 1; compound H3EHGS	17-19
	----- -/--	

☒ Further documents are listed in the continuation of Box C.

☒ See patent family annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

1 April 2008

Date of mailing of the international search report

23/04/2008

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Panday, Narendra

INTERNATIONAL SEARCH REPORT

International application No

PCT/EP2007/064370

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 2005/095305 A (SYNGENTA PARTICIPATIONS AG [CH]; MCKENZIE DUNCAN [CH]; LUCENA JUAN-JOS) 13 October 2005 (2005-10-13) cited in the application the whole document -----	1-19

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/EP2007/064370

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2005095305 A	13-10-2005	AU 2005229417 A1	13-10-2005
		BR PI0509526 A	18-09-2007
		CA 2559762 A1	13-10-2005
		EP 1737805 A1	03-01-2007
		US 2007261453 A1	15-11-2007